Mrs Mallory Maray Woodard, OTR/L, CLT | |
Unit 2060, Apo, AP 96278-2060 | |
(500) 578-4871 | |
(505) 784-3625 |
Full Name | Mrs Mallory Maray Woodard |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | Unit 2060, Apo, Armed Forces Pacific |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215436266 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 5895 (Arizona) | Primary |
Provider Name | Deliver Therapy And Rehabilitation Llc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1033630199 PECOS PAC ID: 4284907080 Enrollment ID: O20170830000166 |
News Archive
A research project at the University of Leicester in conjunction with the University of East Anglia, indicates that early reduction of high blood pressure following stroke is feasible and safe, and both Labetalol & Lisinopril were found to be suitable a medications for this purpose.
Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Mrs Mallory Maray Woodard, OTR/L, CLT Unit 2060, Apo, AP 96278-2060 Ph: (505) 784-8717 | Mrs Mallory Maray Woodard, OTR/L, CLT Unit 2060, Apo, AP 96278-2060 Ph: (500) 578-4871 |
News Archive
A research project at the University of Leicester in conjunction with the University of East Anglia, indicates that early reduction of high blood pressure following stroke is feasible and safe, and both Labetalol & Lisinopril were found to be suitable a medications for this purpose.
Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
› Verified 5 days ago
Jameail Wilson, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 51 Mdg/ Sgoy, Unit 2060, Apo, AP 96278 Phone: 315-784-2157 | |
Sam Kim, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 Phone: 315-737-1184 | |
Holly Thompson, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Bdaach, 549th Hospital Center Usag Humphrey's, Bldg #3030, Apo, AP 96271 Phone: 909-735-9036 | |
Brandi-lee Gonzales, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 Phone: 315-737-7410 | |
Julia E Meurling, MSOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Brian D. Allgood Army Community Hospital (bdaach), Unit 15245; Bldg 3031, Apo, AP 96271 Phone: 956-533-5811 | |
Mrs. Keila Michele Newell, OTR/ L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Unit 45002 Box 349, Apo, AP 96337 Phone: 080-507-00564 |